Patents by Inventor Joel D. Richter

Joel D. Richter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250177431
    Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.
    Type: Application
    Filed: November 12, 2024
    Publication date: June 5, 2025
    Inventors: Joel D. Richter, Fen-Biao Gao
  • Publication number: 20250059604
    Abstract: Provided herein, in various embodiments, are methods of diagnosing a subject as having, or having a propensity to develop, a fragile X-associated disorder (e.g., FXS), methods of prognosing a fragile X-associated disorder (e.g., FXS) in a subject, methods of predicting a treatment outcome of a fragile X-associated disorder (e.g., FXS) in a subject, methods of stratifying a set of subjects having a fragile X-associated disorder, methods of stratifying a population of subjects having, or having a propensity to develop, FXS, and method for assessing the efficacy of a drug for treatment of FXS. Also provided herein, in various embodiments, are assays and systems useful for performing the disclosed methods. The present disclosure also provides methods of treating a subject having FXS.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 20, 2025
    Inventors: Joel D. Richter, Sneha Shah, Elizabeth Berry-Kravis
  • Publication number: 20240417729
    Abstract: Provided herein, in various embodiments, are methods of treating a fragile X-associated disorder (e.g., fragile X syndrome), comprising administering to a subject in need thereof, a therapeutically effective amount of an agent that decreases expression of an aberrant fragile X messenger ribonucleoprotein 1 (FMR1) gene product (e.g., FMR1-217). Also provided herein, in various embodiments, are compositions (e.g., polynucleotides such as antisense oligonucleotides or pharmaceutical compositions) for decreasing expression of an aberrant FMR1 gene product.
    Type: Application
    Filed: June 21, 2024
    Publication date: December 19, 2024
    Inventors: Joel D. Richter, Sneha Shah, Jonathan Watts
  • Patent number: 12161658
    Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: December 10, 2024
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Joel D. Richter, Fen-Biao Gao
  • Publication number: 20210236534
    Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.
    Type: Application
    Filed: December 22, 2020
    Publication date: August 5, 2021
    Inventors: Joel D. Richter, Fen-Biao Gao
  • Patent number: 10905707
    Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 2, 2021
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Joel D. Richter, Fen-Biao Gao
  • Publication number: 20190231808
    Abstract: Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided.
    Type: Application
    Filed: November 9, 2018
    Publication date: August 1, 2019
    Inventors: Joel D. Richter, Fen-Biao Gao